VTRLY (Vitrolife AB) Cash-to-Debt : 0.45 (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Vitrolife AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vitrolife AB's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.45.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vitrolife AB couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Vitrolife AB's Cash-to-Debt or its related term are showing as below:

VTRLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19 Med: 4.75 Max: No Debt
Current: 0.45

During the past 13 years, Vitrolife AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.19. And the median was 4.75.

VTRLY's Cash-to-Debt is ranked worse than
73.46% of 859 companies
in the Medical Devices & Instruments industry
Industry Median: 1.65 vs VTRLY: 0.45

Vitrolife AB Cash-to-Debt Historical Data

The historical data trend for Vitrolife AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vitrolife AB Cash-to-Debt Chart

Vitrolife AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

9.09

15.60

0.25

0.26

0.41

Vitrolife AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															0.36	0.41	0.46	0.41	0.45

Competitive Comparison of Vitrolife AB's Cash-to-Debt

For the Medical Devices subindustry, Vitrolife AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitrolife AB's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Cash-to-Debt falls into.

Vitrolife AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vitrolife AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	83.938	/	(14.331	+	189.323)
	=	0.41

Vitrolife AB's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	90.429	/	(14.86	+	185.551)
	=	0.45

Vitrolife AB (OTCPK:VTRLY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vitrolife AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vitrolife AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (OTCPK:VTRLY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

VITR:Sweden 0YAY:UK VTFN:Germany

Address

Box 9080, Gothenburg, SWE, 400 92

Website

https://www.vitrolife.com

Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.